FDA Approval to Several Drugs in the Pipeline Drives the Global Hypereosinophilic Syndrome Drug Market
Published: May 2022
The global hypereosinophilic syndrome drug market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). All the major players in the global hypereosinophilic syndrome drug market are involved in strategic alliances like acquisitions, partnerships, and collaborations to launch new drugs, to stay competitive in the market. Moreover, the rising US FDA approvals to the drugs developed by major pharmaceutical companies targeting hypereosinophilic syndrome also the factor that is creating significant scope for the market growth.
Increase in No of Patients with Chronic Ailments are Expected to Drive the Growth of the Glycosylated Hemoglobin and C Peptide market
Published: May 2022
The global glycosylated hemoglobin and c peptide market is anticipated to grow at a considerable CAGR during the forecast period. Pharmaceutical companies are working on developing effective drugs which are helpful in the treatment of chronic disorders such as diabetes. No of patients with chronic ailments are increasing in all regions of the world. As per the WHO, 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes.
Increasing Prevalence of Inclusion Body Myositis (IBM) Drives the Market
Published: May 2022
The global inclusion body myositis (IBM) market is expected to grow at a significant CAGR during the forecast period. Muscle weakness and damage are caused by inclusion body myositis, a rare condition. IBM symptoms include progressive weakness in the muscles of the hand, forearm, thigh, and lower leg, but these symptoms vary and are not unique to this condition. The increasing prevalence of IBM around the world is a major factor driving demand for the global Inclusion body myositis market. IBM affects males slightly more often than females. Its prevalence is estimated to be between 10-112 people per 1,000,000 in the general population.
Increased Prevalence of Depression Lead to the High Demand for paroxetine hydrochloride Drug
Published: May 2022
The global paroxetine hydrochloride market is expected to rise at a considerable CAGR during the forecast period (2022-2028). Paroxetine is a drug that is used to treat social mental problems, serious depression, anxiety disorders, panic attacks, and, among other things. the increasing prevalence of mental health disorders and the rising awareness about mental health among people is the major factor driving the market growth. As per WHO, depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years.
Rising Government Initiatives Along with Increasing Geriatric Population and Incidence of Chronic Diseases is Driving the Growth of the Hemodialysis Blood Tubing Sets Market
Published: May 2022
The global hemodialysis blood tubing sets market is anticipated to grow at a significant CAGR during the forecast period. The primary factor contributing to the growth of the market is the rising geriatric population across the globe coupled with the rising incidences of various chronic diseases such as cancer, kidney failure, arthritis, and others. Hemodialysis is a treatment used to filter wastes and water from the blood. This treatment supports to control of blood pressure while balancing minerals such as potassium, sodium, and calcium in the blood. People aged above 50 years usually suffer from the problems such as blood pressure and mineral imbalance.
Increase in Adoption of Various Strategic Initiatives is Driving the Global 3 Phosphoinositide Dependent Protein Kinase 1 Market Growth
Published: May 2022
The global 3 phosphoinositide dependent protein kinase 1 market is anticipated to grow at a significant CAGR during the forecast period. Rise in inclination towards the adoption of various strategic initiative such as product expansion, mergers and acquisitions, partnerships, collaborations, and geographical expansion is the major factor contributing to the growth of the market. For instance, in September 2020, Gilead Sciences, Inc. and Immunomedics entered into a definitive agreement pursuant to which Gilead acquired Immunomedics for $88 per share in cash.
Rising Updates in the Clinical Development of Epacadostat and Other Types of Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
Published: May 2022
The global indoleamine 2,3 dioxygenase 1 market is anticipated to grow at a substantial CAGR during the forecast period. Immunotherapy's recent application in clinical oncology has changed the way we treat advanced human tumors. Immunotherapeutic drugs targeting the CTLA4 and PD-1/PD-L1 axis are currently available to treat a range of malignancies. However, to further improve patient outcomes with these medications, a unique treatment approach is required. indoleamine 2,3-dioxygenase 1 (IDO1) is a rate-limiting enzyme in the peripheral tissue metabolism of the essential amino acid tryptophan.
Rising Cancer Prevalence Globally Ignite the Demand for High Mobility Group Protein B1.
Published: May 2022
The global high mobility group protein B1 market is expected to grow at a significant CAGR during the forecast period (2022-2028). The rising prevalence of cancer such as leukemia and multiple myeloma, globally is a major factor driving market growth. As per the Leukemia & Lymphoma Society (LLS), total of 186,400 people in the US were diagnosed with leukemia, lymphoma or myeloma in 2021.
Rise in Several R&D Spending and Activities Along with Increase in Oncology Research is Driving the Growth of the Cyclin Dependent Kinase (CDK) Inhibitors Market
Published: May 2022
The global cyclin dependent kinase (CDK) inhibitors market is anticipated to grow at a considerable CAGR during the forecast period. CDKs are nutrient metabolic enzymes that regulate the cell cycle. CDK binds to cyclin, forming a complex that works together. In the human body, there are approximately 20 members of the CDK family. Further, an inhibitor is any compound or chemical that inhibits the function of CDKs. Cancer cells proliferate excessively, and (CDK) inhibitors are used as a treatment to regulate this mechanism.
Incidence of Bacterial Diseases has Augmented the Launch of Generic Version of Ertapenem Leading to the Ertapenem Market Growth
Published: May 2022
The global ertapenem market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Ertapenem is also prescribed for patients undergoing certain types of surgery that poses a risk of infection. Incidence of various bacterial diseases is increasing rapidly that is accelerating the demand for ertapenem drug. Pneumonia acquired in hospital settings due to longer patient stays, is often difficult to treat and exists as the comorbidity to various chronic diseases such as cancer, organ transplant. etc. It also interferes with the disease treatment and may be fatal if not treated with broad-spectrum antibiotics such as carbapenem-based antibiotics.